Mumbai, India-based CRO SIRO Clinpharm has named Gopakumar Menon CEO.
SIRO has developed a long-term plan to align with the changing dynamics of the biopharma industry. Menon’s primary charter will be to transform SIRO into a global leader in the CRO and FSP space. He will be responsible for continuing to build and enhance the biopharma service catalog for SIRO's global delivery model across the Americas, Europe and Asia.
"Gopakumar brings with him rich experience in driving business growth and delivering tremendous value for leading companies, including Fortune 1000 companies," said Dr. Gautam Daftary, chairman of SIRO Clinpharm. "Gopakumar has an excellent track record in cultivating partnership-based relationships with Fortune 500 pharmaceutical client base, envisioning cutting-edge business and technical solutions for clients across U.S., Europe, Japan, India, China and Singapore."
"The biopharma industry is undergoing significant transformations. Clients are actively seeking quality service providers from the emerging markets who can understand their specific challenges and partner to build and deliver innovative solutions in a global delivery model," said Menon. "My first priority will be to leverage decades of experience, tremendous value and geographic reach of SIRO to make it the partner of choice for business-critical services of global biopharma leaders."
Menon has been with the pharmaceutical industry for the more than 12 years. Previously he was with Boston-based Sciformix. He has also worked with Cognizant and Satyam in their life sciences divisions, as well as with venture funded start-up organizations.
SIRO Clinpharm has offices in India, Malaysia, the U.S., Israel and Europe in Germany, Romania, Estonia, Greece, Czech Republic and Spain.
Enter Content Here